MX2009004802A - Incremento de las defensas pulmonares del hospedero mediante la administracion del factor estimulador de colonias de granulositos-macrofagos. - Google Patents
Incremento de las defensas pulmonares del hospedero mediante la administracion del factor estimulador de colonias de granulositos-macrofagos.Info
- Publication number
- MX2009004802A MX2009004802A MX2009004802A MX2009004802A MX2009004802A MX 2009004802 A MX2009004802 A MX 2009004802A MX 2009004802 A MX2009004802 A MX 2009004802A MX 2009004802 A MX2009004802 A MX 2009004802A MX 2009004802 A MX2009004802 A MX 2009004802A
- Authority
- MX
- Mexico
- Prior art keywords
- pneumonia
- granulocyte
- fungal
- bacterial
- stimulating factor
- Prior art date
Links
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title abstract 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title abstract 2
- 230000007123 defense Effects 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 230000002685 pulmonary effect Effects 0.000 title abstract 2
- 206010035664 Pneumonia Diseases 0.000 abstract 4
- 230000001580 bacterial effect Effects 0.000 abstract 3
- 230000002538 fungal effect Effects 0.000 abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 206010017533 Fungal infection Diseases 0.000 abstract 2
- 208000031888 Mycoses Diseases 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 206010006448 Bronchiolitis Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 abstract 1
- 241000233872 Pneumocystis carinii Species 0.000 abstract 1
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 abstract 1
- 201000009267 bronchiectasis Diseases 0.000 abstract 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 abstract 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 206010062952 diffuse panbronchiolitis Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86419006P | 2006-11-03 | 2006-11-03 | |
| US94751107P | 2007-07-02 | 2007-07-02 | |
| PCT/DK2007/050161 WO2008052567A2 (en) | 2006-11-03 | 2007-11-02 | Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009004802A true MX2009004802A (es) | 2009-08-12 |
Family
ID=39344625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009004802A MX2009004802A (es) | 2006-11-03 | 2007-11-02 | Incremento de las defensas pulmonares del hospedero mediante la administracion del factor estimulador de colonias de granulositos-macrofagos. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100015217A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2094290B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2010508365A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007315402B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0717958B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2668292C (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009004802A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008052567A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008116470A1 (en) * | 2007-03-26 | 2008-10-02 | Drugrecure Aps | Enhancing pulmonary host defence via administration of granulocyte- colony stimulating factor |
| US9161969B2 (en) | 2011-03-22 | 2015-10-20 | Board Of Regents, The University Of Texas System | Protection against influenza infection by granulocyte-macrophage colony stimulating factor |
| WO2012136224A2 (en) * | 2011-04-07 | 2012-10-11 | Trifoilium Aps | Methods and compositions for enhancing pulmonary host defense in acute and chronic radiation syndrome, therapeutic radiation intervention and cancer therapy |
| WO2013029627A1 (en) * | 2011-08-29 | 2013-03-07 | Trifoilium Aps | Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction |
| US9370189B2 (en) | 2012-05-18 | 2016-06-21 | Syracuse University | Controlling Pseudomonas aeruginosa persister cells with GM-CSF |
| EP2877199A1 (en) * | 2012-07-20 | 2015-06-03 | Trifoilium ApS | Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma |
| WO2014096032A1 (en) * | 2012-12-18 | 2014-06-26 | Trifoilium Aps | Gm-csf for treatment of chronic sinusitis |
| WO2014128173A1 (en) | 2013-02-20 | 2014-08-28 | Trifoilium Aps | Gm-csf for treatment of chronic oral mucositis |
| WO2015110536A1 (en) * | 2014-01-22 | 2015-07-30 | Reponex Pharmaceuticals Aps | Granulocyte-macrophage colony-stimulating factor for the treatment and prevention of severe forms of bronchial asthma |
| EP3662924A1 (en) | 2014-03-07 | 2020-06-10 | Reponex Pharmaceuticals A/S | Compositions for treating lung infections by airway administration |
| EP3145533B8 (en) * | 2014-05-23 | 2024-05-01 | Reponex Pharmaceuticals A/S | Compositions for promoting the healing of wounds |
| US10105415B2 (en) | 2014-07-24 | 2018-10-23 | Reponex Pharmaceuticals A/S | Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease |
| JP7545893B2 (ja) * | 2017-10-16 | 2024-09-05 | ドラッグレキュア エーピーエス | 難治性非結核性マイコバクテリア感染症の治療のためのｇｍ－ｃｓｆ |
| WO2021188883A1 (en) * | 2020-03-20 | 2021-09-23 | The Regents Of The University Of Colorado, A Body Corporate | Methods and compositions for the treatment of viral disease using granulocyte-macrophage colony-stimulating factor (gm-csf) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5391485A (en) * | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US5162111A (en) * | 1986-07-30 | 1992-11-10 | Grabstein Kenneth H | Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US9269067B2 (en) * | 2002-04-04 | 2016-02-23 | Altisource Solutions S.À.R.L. | Method and apparatus for providing selective access to information |
| US7512585B2 (en) | 2002-07-11 | 2009-03-31 | Oracle International Corporation | Support for multiple mechanisms for accessing data stores |
-
2007
- 2007-11-02 US US12/513,215 patent/US20100015217A1/en not_active Abandoned
- 2007-11-02 EP EP07817959.5A patent/EP2094290B1/en active Active
- 2007-11-02 BR BRPI0717958A patent/BRPI0717958B8/pt active IP Right Grant
- 2007-11-02 WO PCT/DK2007/050161 patent/WO2008052567A2/en not_active Ceased
- 2007-11-02 AU AU2007315402A patent/AU2007315402B2/en active Active
- 2007-11-02 JP JP2009535569A patent/JP2010508365A/ja active Pending
- 2007-11-02 CA CA2668292A patent/CA2668292C/en active Active
- 2007-11-02 MX MX2009004802A patent/MX2009004802A/es active IP Right Grant
-
2013
- 2013-09-25 JP JP2013198117A patent/JP2014028839A/ja active Pending
-
2015
- 2015-10-16 JP JP2015204558A patent/JP6001151B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008052567A3 (en) | 2009-01-22 |
| US20100015217A1 (en) | 2010-01-21 |
| JP6001151B2 (ja) | 2016-10-05 |
| BRPI0717958B1 (pt) | 2019-12-10 |
| AU2007315402B2 (en) | 2013-05-16 |
| JP2016040300A (ja) | 2016-03-24 |
| JP2014028839A (ja) | 2014-02-13 |
| WO2008052567A2 (en) | 2008-05-08 |
| EP2094290A2 (en) | 2009-09-02 |
| JP2010508365A (ja) | 2010-03-18 |
| CA2668292C (en) | 2018-04-03 |
| BRPI0717958B8 (pt) | 2021-05-25 |
| AU2007315402A1 (en) | 2008-05-08 |
| BRPI0717958A2 (pt) | 2013-11-05 |
| CA2668292A1 (en) | 2008-05-08 |
| EP2094290B1 (en) | 2017-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009004802A (es) | Incremento de las defensas pulmonares del hospedero mediante la administracion del factor estimulador de colonias de granulositos-macrofagos. | |
| JP2010508365A5 (cg-RX-API-DMAC7.html) | ||
| MX2013013503A (es) | Composiciones de vancomicina en polvo seco y metodos asociados. | |
| WO2012047674A3 (en) | Methods and compositions for disease treatment using inhalation | |
| JP2014028839A5 (cg-RX-API-DMAC7.html) | ||
| EP4620525A3 (en) | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | |
| WO2008147482A3 (en) | Methods and compositions for improving immune responses | |
| WO2009099998A3 (en) | Therapeutic treatment for lung conditions | |
| HRP20200661T1 (hr) | Razine ceramida u liječenju i prevenciji infekcija | |
| Hansbro et al. | Toll-like receptors in COPD | |
| NZ715882A (en) | Tissue targeted antigenic activation of the immune response to treat cancers | |
| MX2020010977A (es) | Procedimientos de tratamiento de infecciones fúngicas. | |
| CN102228309B (zh) | 小茴香吸品及其制法 | |
| JP2014529614A5 (cg-RX-API-DMAC7.html) | ||
| RU2014111818A (ru) | Композиции и способы для лечения или предупреждения легочной дисфункции, вызываемой лучевой терапией или химиотерапией | |
| WO2010025577A3 (de) | Zubereitung zur prävention und/oder behandlung und/oder verhinderung der weiterverbreitung von atemwegserkrankungen | |
| AR064883A1 (es) | Aumento de las defensas pulmonares del huesped mediante la administracion de factor estimulador de colonias de granulocitos-macrofagos | |
| CN103690914B (zh) | 一种治疗风寒犯肺证型肺病的中药 | |
| Kobayashi et al. | Hydrogen Gas Inhalation Ameliorates Lung And Distal Organ Injury In A Murine Aspiration Pneumonia Model | |
| Okamoto et al. | Muc5b expression is increased in a murine model of hypersensitivity pneumonitis | |
| Daqiang et al. | Effect of sodium houttuyfonate on symptom pattern of lung-Qi deficiency in rats induced by bacterialbiofilm infection | |
| Pesut et al. | Bilateral pulmonary shadows and incapsulated mediastinal effusion in a patient with respiratory blastoschizomycosis | |
| Palmer et al. | Can Multi-Drug Resistant Organisms (MDRO) Be Treated By Aerosolized Antibiotics? | |
| Corris et al. | A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation | |
| Kimura et al. | Effects of PC945, a novel antifungal agent optimised for lung delivery, on Candida albicans lung infection in mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |